Firefly Luciferase Raji Cell Line
Recombinant Raji cells constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
| Name | Ordering Information |
| Thaw Medium 2 | BPS Bioscience #60184 |
| Growth Medium 2D | BPS Bioscience #79639 |
| 96-well Tissue Culture-treated White Clear-bottom Assay Plate | Corning #3610 |
| ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
| Luminometer |
Media Required for Cell Culture
Thaw Medium 2 (BPS Bioscience #60184):
RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.
Growth Medium 2D (BPS Bioscience #79639):
RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 200 μg/ml of Hygromycin B.
The cell line has been screened to confirm the absence of Mycoplasma species.
The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells. The Firefly Luciferase – Raji Recombinant Cell Line makes an excellent target for CAR-T or NK cells targeting CD19, CD20, or CD22. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cells killing upon co-culture with CAR-T or NK cells.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.